pharmaphorum

DECEMBER 16, 2020

Episode four of Kantar Health’s Health Heroes podcast tackles pharma’s rare disease challenges, the role of patient registries and hears a moving story about the rare genetic disorder Tay-Sachs disease. The podcast finishes up with an overview from Geneviève on the current outlook for rare diseases.

Life Science 52

Life Science Pharma Companies Genetics Research 52

pharmaphorum

FEBRUARY 17, 2021

One group excelling in this space is the Genetic Alliance. Their work ranges from developing new services in partnership with the National Health Service (NHS) to working with the All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions, and the Department of Health on the UK Strategy for Rare Diseases.

Life Science 97

Life Science Branding Genetics Trials 97

pharmaphorum

JULY 7, 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. As this issue’s contributors discuss, by working together pharma companies and healthcare providers can significantly enhance oncology treatment for patients. New horizons in breast cancer care.

Vaccination 52

Vaccination Vaccine Life Science Trials 52

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

AUGUST 21, 2023

This attachment halts the advancement of the genetic disorder through a reduction in the formation of fresh, abnormal bone growth. The active ingredient in Sohonos, palovarotene, functions as an agonist of the retinoic acid receptor gamma, which is present in cells that are involved in bone formation.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

pharmaphorum

JUNE 20, 2022

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. “The key headline is that rare diseases are not a niche.

Drugs 52

Drugs Marketing Life Science Regulation 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

DECEMBER 16, 2022

Of significant interest to the pharma industry are the suggestions in the draft text that money granted for research on infectious diseases could include specifications on how eventual products could be marketed. In response, some companies, such as Pfizer , have made commitments to sell products to the countries at non-profit prices.

Vaccination 86

Vaccination Vaccine Production Licensing 86

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. With the advancement in technology, today diagnostics testing such as neurological examination, brain scans, genetic screening, and other tests are available to examine the occurrence of Neurological Conditions.

Marketing 98

Marketing Genetics Development Clinical Development 98

Drug Discovery World

FEBRUARY 6, 2024

Biopharma and biotech companies without these capabilities are keen to harness these technologies and the number of strategic partnerships with such companies is accelerating at an unprecedented rate. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The primary drivers for growth include increasing cancer and genetic cases and predicated applicability of CGT as a treatment.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. SK Life Science is a subsidiary of SK, a South Korean holding company.

Research 264

Research Gene Gene Therapy Genome 264

pharmaphorum

MARCH 28, 2022

Built under a government tender, AION Labs comprises four large international pharma companies – AstraZeneca , Merck, Pfizer , and Teva – and another core partner, the Israel Biotech Fund. But it always starts with the biology or the genetic pool that makes the natural antibodies. The partnership. About the author .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

pharmaphorum

APRIL 8, 2021

But life sciences discussions seemed to generally be optimistic about the future of the world’s COVID response – whilst also acknowledging the difficult questions the sector now faces in the future. In the UK we have world leading genetic sequencing capabilities. BioNTech seeks “new kind of pharma company”.

Development 82

Development Drugs Vaccination Vaccine 82

Drug Discovery World

OCTOBER 4, 2022

Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. . This year has seen some major deals announced by big pharma companies. In the UK, six universities received £4.25

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Recro – CDMO company Recro announced David Enloe as its new president and CEO.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 78

Marketing Gene Silencing Gene Drugs 78

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

OCTOBER 26, 2022

And the company lives its commitment to patient centricity through all its operations, Chiesi explained. For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Caring for a global community.

Development 86

Development Trials Marketing Life Science 86

XTalks

NOVEMBER 16, 2021

Dassault Systèmes acquired the company in 2019 and de Vries was serving as the Life Sciences & Healthcare vice-chair for the new parent company. We will truly miss Glen, but his dreams — which we share — live on: we will pursue progress in life sciences and healthcare as passionately as he did.”.

Life Science 98

Life Science Clinical Research Pharma Companies Engineer 98

Drug Discovery World

JANUARY 24, 2023

” 4,5,6 Asking the right questions Norstella is a newly formed company that aims to guide life sciences companies through drug development so patients can access therapies quicker. He says: “Progress will need to be done deliberately as industry works to solve the many regulatory challenges expected to arise.

Clinical Trials 97

Clinical Trials Clinical Trials Drugs Trials 97

pharmaphorum

DECEMBER 6, 2022

The importance of health data to the life science industry is growing just as rapidly as the technology enabling its capture is advancing. A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped.

Genome Project 95

Genome Project Research Genome Genomics 95

Pharmaceutical Technology

MAY 24, 2023

The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. CGT drugs fall into two major categories: autologous and allogeneic.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

XTalks

AUGUST 17, 2020

A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

SEPTEMBER 7, 2022

The industry may need to carry out behavioural studies to better understand how to recruit and involve these populations, as it is crucial to understand the genetic differences between demographics. Whilst this is an early area of research, pharma can turn the dial now. The same is true for Asian and Hispanic populations.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Genetics 95

Drug Discovery World

JULY 19, 2023

Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science.

Genome 52

Genome Genomics Bioinformatics Genetics 52

XTalks

JANUARY 15, 2024

Personalized Medicine Driving Targeted Trials In 2022, personalized medicines accounted for 34 percent of all new FDA drug approvals, as reported by the Personalized Medicine Coalition, reflecting a robust industry focus on treatments tailored to individual genetic profiles.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Clinical Research 105

XTalks

OCTOBER 15, 2021

The Lacks family is also concerned over the wide availability of Lacks’ genetic material, saying that “some of the most private information about Ms. However, the agreement did not include a share of any profits that researchers or pharma companies may make from use of the cells.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctors 105

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% in 2022, a steep decline compared to the record 6.8% the industry experienced in 2021.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

XTalks

AUGUST 18, 2021

These samples are often made available to support the research efforts of pharma companies developing new antibacterial agents. Historically, the top 50 pharma companies by sales have been steadily ending their anti-infective, and in particular, their AMR drug development programs and have had little incentive to get back in the game.

Development 105

Development Bacteria Drugs Vaccination 105

XTalks

OCTOBER 1, 2020

Sooter has also found success in industry, leading and bringing together the work of different teams of researchers at NeuBase to help drive the company’s goal of developing cures and treatments for genetic diseases, including Huntington’s Disease. Funding in the Life Science Industry vs. Academia.

Scientist 52

Scientist In-Vitro Research Life Science 52

Pharmaceutical Technology

MAY 26, 2023

After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s Life Sciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment. Rapid production will potentially enable researchers to overcome an industry bottleneck.

DNA 130

DNA Manufacturing Gene Therapy Gene 130